Subscribe
Cameron Marshall of Carpmaels & Ransford
26 September 2024NewsUnified Patent CourtSarah Speight

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Cameron Marshall, partner at Carpmaels, offers a behind-the-scenes snapshot of working a UPC case with tight deadlines and an unusual result, finds Sarah Speight.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024   The president of the appeals court reveals his thinking on transparency, bringing more countries on board, and the hidden delays in the EU Commission’s SEP plan.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024   The president of the appeals court reveals his thinking on transparency, bringing more countries on board, and the hidden delays in the EU Commission’s SEP plan.

More on this story

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024   The president of the appeals court reveals his thinking on transparency, bringing more countries on board, and the hidden delays in the EU Commission’s SEP plan.

More features

Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal